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The aim of this article is to review the research into the main peripheral appetite signals altered in human obesity, together with
their modiﬁcations after body weight loss with diet and exercise and after bariatric surgery, which may be relevant to strategies for
obesity treatment. Body weight homeostasis involves the gut–brain axis, a complex and highly coordinated system of peripheral
appetite hormones and centrally mediated neuronal regulation. The list of peripheral anorexigenic and orexigenic physiological
factors in both animals and humans is intimidating and expanding, but anorexigenic glucagon-like peptide 1 (GLP-1),
cholecystokinin (CCK), peptide YY (PYY) and orexigenic ghrelin from the gastrointestinal tract, pancreatic polypeptide (PP) from the
pancreas and anorexigenic leptin from adiposites remain the most widely studied hormones. Homeostatic control of food intake
occurs in humans, although its relative importance for eating behaviour is uncertain, compared with social and environmental
inﬂuences. There are perturbations in the gut–brain axis in obese compared with lean individuals, as well as in weight-reduced
obese individuals. Fasting and postprandial levels of gut hormones change when obese individuals lose weight, either with surgical
or with dietary and/or exercise interventions. Diet-induced weight loss results in long-term changes in appetite gut hormones,
postulated to favour increased appetite and weight regain while exercise programmes modify responses in a direction expected to
enhance satiety and permit weight loss and/or maintenance. Sustained weight loss achieved by bariatric surgery may in part be
mediated via favourable changes to gut hormones. Future work will be necessary to fully elucidate the role of each element of the
axis, and whether modifying these signals can reduce the risk of obesity.
International Journal of Obesity (2016) 40, 622–632; doi:10.1038/ijo.2015.220
INTRODUCTION
Projections suggest that, by 2030, obesity prevalence may reach
over 45% of the entire US population, and 48% in the United
Kingdom.1 Behind this lies a progressive rise in body fat of
individuals with age, that is, the disease process of obesity, as
recognized by the American Medical Association.2 By age 65,
almost 40% of UK adults are now obese, and only 15% of men and
28% of women have a ‘normal’ body mass index (BMI) of 18.5–
25 kgm− 2.3
Rapidly growing obesity research is now shedding light on the
complex and interrelated biological and psychosocial under-
pinnings of appetite regulation and eating behaviour. The
changing food environment and food culture have a major role
in the recent rise in obesity: with ready availability of attractive
high-calorie foods, often in excessive portion sizes, and sedentary
lifestyles all now regarded as normal.4 However, a body of
evidence supports a continuing role for the gut–brain axis in
regulation of food intake and the maintenance of body weight.5–8
Thus, a complex array of signals from peripheral and central
nervous systems, possibly under epigenetic programming, inter-
acts with psychological and social factors to determine energy
balance and body weight homeostasis.5
A great deal of research has been applied to the search for
genetic factors behind obesity. Although many single gene
variants have been discovered, their individual and indeed
cumulative effect sizes are rather small, and they do not appear
to account for the dramatic epidemic rise of obesity
internationally. Most appear to be associated with alterations in
appetite/food intake, rather than metabolic effects on energy
balance.9 It is possible that the rapidly growing study of
epigenetics will reveal more mechanisms.
It is difﬁcult to disentangle altered physiological factors that are
possibly contributory, from the multiple biological consequences
of weight gain and obesity. The underlying processes do not
emerge only when people reach an arbitrary BMI or waist cutoff
for ‘obesity’, but exert causal inﬂuences from the earliest stages as
body fat content begins to rise. The combined effects of
physiological factors are usually only sufﬁcient to generate weight
gains of 0.5–1 kg year− 1, which implies energy imbalances of
around 10–20 kcal day− 1, on average. This amount (o1% of
metabolic rate and energy requirements)10 is too small to detect
by calorimetric methods, but is enough to cause weight gains of
up to 40–50 kg over an adult life.11 These considerations indicate
the signiﬁcant difﬁculties that face any attempt to provide
evidence for a quantitative mechanistic physiological explanation
underlying obesity.
Over the past 20 years, there has been a glut of information on
the physiological control of appetite in animal models; more than
30 gut hormones, neuropeptides and neurotransmitters are now
known to affect appetite (Table 1). Many have been documented
in both animals and humans, so might have roles in developing or
treating obesity. Pharmacological agents directed at the com-
pounds involved in physiological control of appetite have
increasingly been investigated.12 However, even a drug that
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Table 1. Hormones, neuropeptides and neurotransmitters involved in appetite regulation based on animal and/or clinical studies
Hormone, neuropeptide,
neurotransmitter
Primary source for appetite
regulation
Proposed mechanism of action on appetite Level of evidence
Anorexigenic factors
α-Melanocyte-
stimulating hormone
(α-MSH)
Hypothalamus Stimulates hypothalamic MC3/4 receptors 2(ref. 119) (1 RCT)
Acetylcholine CNS; PNS Nicotinic acetylcholine receptor-mediated
modulation of hypothalamic circuits regulating
appetite and cortico-limbic-striatal reward circuits
2(ref. 120) (3 RCTs)
Adrenocorticotropic
hormone (ACTH)
Hypothalamus Stimulates hypothalamic MC3/4 receptors 2(ref. 119) (4 RCTs)
Amylin Pancreatic β cells (co-secreted
with insulin)
Delays gastric emptying; targets the hindbrain and
hypothalamus
4(ref. 121) (5 RCTs)
Apolipoprotein A-IV Intestinal epithelial cells Inhibits gastric motility, targets the hypothalamus 1(ref. 122)
Catecholamines
(dopamine,
epinephrine,
norepinephrine)
Brain stem, adrenal gland Acute decrease in food intake 2 (ref. 123) (14 RCTs)
Cocaine- and
amphetamine-
regulated transcript
(CART) peptide
Hypothalamus Modulates hypothalamic and hindbrain circuits 1(ref. 124)
Cholecystokinin (CCK) Duodenal/jejunal I cells Delays gastric emptying; targets the vagus nerve,
hindbrain, and hypothalamus
2(ref. 41) (37 RCTs)
Enterostatin Exocrine pancreas Inhibits fat intake, targets the hypothalamus 2(ref. 125) (1 RCT)
Gastrin-releasing
peptide (GRP)
Gastric myenteric neurons Contributes to meal termination 2(ref. 126) (1 RCT)
Glucagon Pancreatic α cells Modulates gastric emptying and vagal tone 4(ref. 127) (large number of
RCTs, although these may
include studies of GLP-1)
Glucagon-like peptide
1 (GLP-1)
Intestinal L cells (co-secreted
with PYY, OXM)
Decreases gastric emptying, promotes insulin
secretion, suppresses glucagon secretion; targets
the vagus nerve, hindbrain, and hypothalamus
4(ref. 127) (63 RCTs)
Insulin Pancreatic β cells Targets the hypothalamus 4 (4 systematic reviews127–130)
(136 RCTs)
Leptin White adipose tissue, stomach
(secreted in proportion to adipose
volume and total fat mass)
Signals the brainstem and arcuate nucleus of the
hypothalamus when fat stores are low
2(ref. 86) (68 RCTs)
Neuromedin B (NMB) Gastric myenteric neurons Contributes to meal termination 0(ref. 131)
Neurotensin Gastrointestinal enteroendocrine
cells
Decrease in food intake is acute only 1(ref. 132)
Obestatin Stomach, intestine Decreases food intake, slows gastric emptying 2(ref. 74) (2 RCTs)
Oxyntomodulin
(OXM)
Intestinal L cells (co-secreted
with GLP-1, PYY)
Delays gastric emptying; targets the hypothalamus 2(ref. 133) (3 RCTs)
Oxytocin Hypothalamus Projections to caudal brainstem; inhibits gastric
emptying
2(ref. 134) (1 RCT)
Pancreatic
polypeptide (PP)
Pancreatic F cells Delays gastric emptying; targets the vagus nerve
and hindbrain
2(ref. 42) (8 RCTs)
Peptide tyrosine-
tyrosine (PYY)
Intestinal L cells (co-secreted
with GLP-1, OXM)
Delays gastric emptying; targets the vagus nerve
and hypothalamus
2(ref. 135) (50 RCTs)
Serotonin Midbrain, hindbrain Targets hypothalamus 4(ref. 136) (21 RCTs)
Vasoactive intestinal
polypeptide (VIP)
Intestine, pancreas Targets hypothalamus 1(ref. 137)
Orexigenic factors
Agouti-related
peptide (AgRP)
Hypothalamus MC3/4 receptor antagonist 2(ref. 138) (2 RCTs)
Endocannabinoids Hypothalamus Cannabinoid receptors widely distributed
throughout the CNS
2(ref. 139) (2 RCTs)
γ-aminobutyric acid
(GABA)
Ubiquitous in CNS GABA/AgRP co-expressing neurons targeting the
parabrachial nucleus of the hypothalamus
0(ref. 140)
Galanin Widely distributed in CNS, PNS
and gut
Central stimulation of food intake mediated by
galanin receptor-1; modulates hippocampal
circuits
2(ref. 141) (1 RCT)
Ghrelin Gastric antrum and fundus Increases gastric emptying, decreases insulin
secretion; targets the vagus nerve, hindbrain and
hypothalamus
2(ref. 142) (114 RCTs)
Glutamate Ubiquitous in CNS Stimulates AgRP/NPY-expressing neurons in the
hypothalamus
1(ref. 143)
Melanin-
concentrating
hormone (MCH)
Hypothalamus MCH neurons have widespread projections
throughout the brain
1(ref. 144)
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could completely reverse one major mechanism affecting appetite
may not be expected to have an effect on body weight greater
than perhaps 5–10%13 when used as monotherapy, as other
mechanisms remain active, and because beyond young childhood
humans eat in response to a wide variety of physical or sensory
cues and social triggers.14 The experience of eating for pleasure,
akin to addictive behaviours (rather than appetite), is common-
place for most people even without obesity, and eating as a result
of boredom is also very common. Social marketing by the food
industry has exploited this to great advantage.
The gut–brain axis is the physiological driver of satiation in
humans. Meal ingestion results in gastric distension and produc-
tion of peptide hormones by enteroendocrine cells, both of which
can promote a feeling of fullness/satiety, and a desire to stop
eating; this topic has been extensively reviewed elsewhere.15–17
Peptide hormones generated in the gastrointestinal (GI) tract and
adipose tissue modulate appetite in both animal and human
studies (Table 1). Peptides released, in response to ingested food,
from multiple sites in the gut (including the stomach, proximal/
distal small intestine, pancreas and colon), activate vagal afferent
nerves that innervate brain regions involved in the immediate
need for food intake.18,19 Peripheral signals from adipose tissue
and the gut are integrated in the hypothalamus to inﬂuence short-
term food intake and long-term energy balance; centrally released
hormones and neurotransmitters also participate in appetite
regulation.20–22 Cross-talk between peripheral satiety signals and
hypothalamic and brainstem centres represents an integrative
regulatory system for feeding, energy balance and body
composition.
Homeostatic and hedonic systems in the brain also inﬂuence
appetite and satiety. The physiologic need to eat during negative
energy balance is a primitive survival function, mediated through
the hindbrain and hypothalamus.5,23 In contrast, a desire to
consume attractive foods arises from mesolimbic reward circuits
and regions in the orbitofrontal cortex that regulates hedonic food
intake based on the sensations of taste, smell, texture and
sight.23–25 The hedonic systems are in constant interaction with
homeostatic mechanisms and sensory attractiveness of foods can
become dominant to contribute to weight gain and obesity. These
mechanisms cannot be considered totally separate, indeed gut
hormones such as ghrelin can alter the hedonic perceptions of
food on presentation and consumption in response to negative
energy balance, perhaps via the FTO gene expression or through
dopaminergic mechanisms.26 A possible partial explanation for
the recent obesity epidemic is that sensory stimulation related to
food (that is, hedonic inputs) and overconsumption of palatable,
energy-dense meals has increased markedly in society, whereas
basic homeostatic satiety controls have remained stable.27,28
The concept of a physiological ‘set point’ whereby energy
intake is automatically adjusted to maintain weight, or a speciﬁc
component of body composition, is now relatively old, but begs
questions about mechanisms. New evidence may suggest that
there are structural changes in the hypothalamus, which could be
responsible for resetting the putative set point in such a way that
appetite will defend an increased body weight.29 The extent to
which this might be relevant outside cases of hypothalamic
obesity is uncertain, and there remains evidence that some people
can adapt to live with a lower body weight after intentional
weight loss.
This review aimed to provide a listing and concise summary of
the hormones currently recognized to affect appetite, as a
reference point for clinicians and researchers. It followed a
structured approach to reach the totality of the published
literature, to examine the currently available evidence on the
biological regulation of appetite and the dysregulated gut- and
adipose tissue-derived hormone signalling in overweight and
obese individuals. It evaluates evidence on peripheral hormone
responses to weight loss, achieved by either dietary and exercise
interventions or surgical procedures, and aims to identify potential
links between changes in hormone levels and obesity with a view
to determine which changes are secondary and which may be
primary and potentially causal.
MATERIALS AND METHODS
Studies were identiﬁed by searching PubMed and Embase
electronic databases for peer-reviewed, English-language publica-
tions between June 2008 and July 2013. Original studies were
identiﬁed from the two databases by searching for the following
terms in the title or abstract: ‘appetite’, ‘satiety’, ‘satiation’, ‘satiety
response’ or ‘post-meal satiety’; in conjunction with: ‘obesity’,
‘body fat’, ‘weight gain’, ‘weight reduction’, ‘weight loss’, ‘waist
circumference’ or ‘body mass index’; and together with: ‘hormone
(s)’, ‘peptide(s)’, ‘glucagon-like peptide 1’, ‘peptide YY’, ‘leptin’,
‘ghrelin’, ‘pancreatic polypeptide’, ‘obestatin’ or ‘cholecystokinin’.
Approximately 600 papers were identiﬁed and reviewed for
relevance by two reviewers. Original studies were chosen for
inclusion if they contained direct comparisons of hormonal satiety
responses to a test meal in overweight or obese subjects versus
lean controls. Studies of hormonal satiety responses before and
post gastric bypass surgery or other weight loss interventions
were included, as were neuroimaging studies that examined the
effects of obesity on brain activation. The examination of
bibliographies from published papers identiﬁed important sources
published earlier than 2008.
There is a large body of literature on obesity and satiation in
animals; articles were selected from the search results to illustrate
Table 1. (Continued )
Hormone, neuropeptide,
neurotransmitter
Primary source for appetite
regulation
Proposed mechanism of action on appetite Level of evidence
Motilin Small intestine Increases gastric motility, targets vagus nerve 1(ref. 145)
Neuropeptide W
(NPW)
Hypothalamus, stomach Orexigenic: activation of melanin-concentrating
hormone- and orexin-containing neurons
0(ref. 146)
Neuropeptide Y (NPY) Hypothalamus Stimulates Y1 and Y5 receptors; modulates
hypothalamic circuits
2(ref. 141) (5 RCTs)
Orexin (hypocretin) Central: Hypothalamus
Periphery: enteric plexus, mucous
and musculature in the gut
Stimulates gastric emptying 1(ref. 147)
Visfatin Visceral adipose tissue Potentially modulates hypothalamic circuits 1(ref. 148)
Abbreviations: CNS, central nervous system; MC, melanocortin; PNS, peripheral nervous system; RCT, randomized controlled trial. 0= animal studies only;
1=observational clinical studies; 2= randomized controlled trials; 3= systematic reviews of observational studies; 4= systematic reviews of randomized
controlled trials (with or without observational studies as well).
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the hormones, peptides and neurotransmitters listed in Table 1,
with additional focused searches conducted to conﬁrm the level
of evidence (where 0 = animal studies only, 1 = observational
clinical studies, 2 = randomized controlled trials, 3 = systematic
reviews of observational studies and 4= systematic reviews of
randomized controlled trials (with or without additional observa-
tional studies)). A number of peptides have not been included in
the present review. For example, tumour necrosis factor was
excluded because the subject population in most studies
comprised patients with cancer or undergoing haemodialysis.
Pro-opiomelanocortin was also excluded, as it is a precursor for
adrenocorticotropic hormone and α-melanocyte-stimulating hor-
mone, both of which are included in this review. Some additional
peptides originally thought to inﬂuence eating habits no longer ﬁt
into either anorexigenic or orexigenic categories (for example,
adiponectin has evidence for both; obestatin was originally
thought to be anorexigenic, but more recent studies have not
conﬁrmed this and even suggested that the activity of obestatin
may be dependent on ghrelin30). When reviewing Table 1, note
that preclinical models are not entirely analogous to obesity in
humans, as stress-induced changes in feeding behaviour may
result from different animal handling methods.16,31 Food intake by
humans is, in large part, inﬂuenced by external factors and
cognitive processes that are not operative in animals.5,27 Thus,
although there is an ongoing contribution of animal studies
towards better understanding of the mechanisms underlying
obesity, this review focuses primarily on ﬁndings from studies in
humans, with a view to establishing which alterations in
mechanisms are secondary consequences of excess adiposity,
which may be causal, and which may retain some potential for
exploitation in obesity treatment.
Obesity and dysregulated appetite signalling
Findings from studies comparing the effects of obesity in humans
on concentrations of peripheral appetite hormones in the fasting
state or following a test meal and evidence on peripheral
hormone responses to weight loss induced by dietary and/or
exercise interventions or surgical interventions are reviewed.
Emphasis has been placed on the hormones that have been the
most widely studied (Table 1). In research of this kind, it is
important to distinguish between dynamic effects arising from
acute negative energy balance, and static effects that reﬂect a
change in body composition. It is therefore important to include a
period of weight stability after weight loss to remove the effects of
acute energy imbalance, while recognizing that the components
of energy balance may be different during weight stability (energy
balance) after weight loss, for example, there may be altered
macronutrient composition of the diet, or greater physical activity.
It is implicit in any analysis of endocrine functions that hormone
actions must always reﬂect both circulating concentrations and
also receptor number and sensitivity. In many cases, while it is
relatively straightforward to measure plasma concentration, and
sometimes circulating receptors, it is usually impossible to assess
receptor or post-receptor functions in vivo. Sensitivity or resistance
to a hormone action is invoked empirically when there are
different responses to the same concentration.
Glucagon-like peptide 1. Glucagon-like peptide (GLP-1) (Table 1)
is the product of post-translational processing of pro-glucagon in
the gut and the brain.32 In the gut, GLP-1 is secreted primarily
from enteroendocrine L cells located in the distal jejunum and
ileum, and its release is stimulated by carbohydrate and fat
intake.33,34 GLP-1 receptors are widely distributed in the brain, in
peripheral organs such as the pancreatic islets, and in the whole GI
tract. In the brain, GLP-1 receptors are found in areas that are
implicated in the control of food intake and energy balance. GLP-1
has several other physiological functions: it acts as a strong
incretin, that is, stimulates glucose-induced insulin release, and it
inhibits glucagon release.35,36 In addition, GLP-1 activates the ‘ileal
brake’ by slowing the rate of gastric emptying, which slows
nutrient absorption and contributes to the reduction of post-
prandial glycaemia and enhanced satiety,34,35 and may explain
nausea as a transient effect of GLP-1 receptor agonists.37 Both
central and peripheral administration of GLP-1 have been shown
to reduce food intake. Secretion of GLP-1 in response to food
intake is biphasic: the early phase occurs within 10–15min after
food ingestion with a second peak at 30–60min.34 After release,
GLP-1 is rapidly inactivated and has a plasma half-life of less than
2min.
Obesity has been associated with an attenuated postprandial
GLP-1 response to test meals in a number of cross-sectional and
longitudinal studies.38–40 Preprandial GLP-1 levels were similar for
overweight/obese adults compared with normal-weight controls
in a study conducted by Adam and Westerterp-Plantenga,38 but
the postprandial GLP-1 response was signiﬁcantly blunted in
overweight/obese subjects 30min after a test meal compared
with control subjects. Another study revealed that while in
normal-weight subjects GLP-1 levels increased 10min after a
standard liquid meal, in obese subjects GLP-1 levels declined
markedly in the ﬁrst 20 min (Figure 1).39 These data, however,
contrast with a similar study by Bowen et al.41 in which
postprandial GLP-1 levels were signiﬁcantly greater in obese
versus lean subjects after consumption of a buffet lunch. It should
be noted that in this study the fasting concentrations of GLP-1
were also signiﬁcantly higher in the obese individuals. Thus, the
postprandial response may have been inﬂuenced by the fasting
GLP-1 concentration rather than by obesity status.
Studies have examined the effects of dietary interventions for
weight loss on GLP-1 levels. After a reduction of ⩾ 8% of an
initially obese body weight, with an 8-week low-energy diet
(1000 kcal day− 1) and a 2- to 3-week control diet standardization
period, lower levels of fasting GLP-1 and greater appetite were
observed compared with assessments in the same patients after a
6-month high monounsaturated fat dietary intervention which
was accompanied by a modest (3.6 kg, 4.2%) weight regain.42
Another study monitored patients after an 8-week very-low-
calorie diet (500–550 kcal day− 1), followed by a 2-week weight
stabilization period and a 52-week weight maintenance phase.43
After weight stabilization at week 10, patients had a mean weight
loss of 14% of initial body weight. Patients regained some weight
during the maintenance phase, remaining a mean of 8% below
Figure 1. GLP-1 responses to a liquid test meal in 19 normal-weight
and 20 obese subjects.39 Reproduced with permission.
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their initial body weight at week 62. Postprandial GLP-1 levels
after 62 weeks were signiﬁcantly lower than at baseline. The
above studies support the view that modest diet-induced weight
loss can result in long-term reductions in GLP-1, postulated to
favour increased appetite and weight regain. This may at least in
part explain why weight loss through caloric restriction is often so
difﬁcult to achieve and/or maintain for obese individuals.
Although caloric restriction-induced weight loss reduces GLP-1
levels, weight loss with exercise was reported to induce a
response in the opposite direction. Martins et al.44 were the ﬁrst
to examine the effect of aerobic exercise training on fasting and
postprandial levels of GLP-1 in obese individuals; a 12-week
supervised exercise training programme (500 kcal of treadmill
walking or running 5 days per week) had no impact of fasting
GLP-1 concentration, but tended to increase its postprandial
release.44 The tendency for a beneﬁcial change in GLP-1 levels
may explain why long-term exercise training typically permits
body weight reduction and helps maintenance. The recent meta-
analysis revealed a small mean effect for acute exercise to increase
GLP-1 levels in normal-weight individuals.45 It remains unclear
whether these ﬁndings apply to obese and overweight individuals.
Peptide YY. Peptide YY (PYY) is a satiety hormone whose
anorexigenic effects are attributed to delayed gastric emptying
(that is, the ileal brake) that is dose related and dependent on the
amount of fat in the meal.46 PYY is co-secreted with GLP-1 by L
cells in the lower intestine.47,48 Postprandial levels of PYY peak
within 2 h of eating and are proportional to the size and type
(fat4protein4carbohydrate) of the ingested meal.49,50 Fat intake
is the strongest stimulant of PYY secretion, whereas carbohydrate
intake has a limited effect in obese or non-obese individuals.51,52
Several studies have documented the obesity-related attenua-
tion of postprandial responses in PYY levels.53–55 For example, in
one study, the PYY response in obese subjects was signiﬁcantly
lower than in normal-weight controls after each of six test meals
of increasing caloric content (Figure 2). This attenuated response
corresponded with signiﬁcantly lower subjective ratings of fullness
in obese subjects, beginning 30min after the meal and persisting
for 3 h.49 Zwirska-Korczala et al.55 also observed blunted
postprandial PYY responses in obese and morbidly obese women
compared with lean control subjects. Racial differences in PYY
responses were examined in another study of obese and lean
women.53 Signiﬁcantly lower postprandial PYY levels were noted
in obese black women compared with lean black women, lean
white women or obese white women; unfortunately, given the
known racial differences in body compositions, these authors did
not report body fat content or any relationship between PYY levels
and body composition.
Similar to the ﬁndings with GLP-1 levels, in obese subjects
weight loss of ⩾ 8% from an 8-week low-energy diet followed by a
2- to 3-week weight stabilization period resulted in decreased
levels of fasting PYY and increased hunger.42 Short-term diet-
induced weight loss in another study also resulted in signiﬁcant
reductions in postprandial PYY levels and a signiﬁcant increase in
subjective appetite that persisted over a 12-month weight
maintenance phase.43
In contrast to dietary intervention studies, exercise studies
conducted on overweight and obese individuals have reported
increases or no change in PYY levels. An increase in fasting plasma
PYY concentrations after 32 weeks of exercise training occurred in
overweight male and female adolescents who experienced a
signiﬁcant decrease in body fat.56 Similarly, a signiﬁcant increase
in fasting PYY concentrations was reported in obese children who
lost body weight following a 1-year diet and exercise
intervention.57 One report noted a tendency for increased
postprandial PYY concentrations in overweight and obese men
and women after a 12-week exercise intervention.44 More recently,
a study by Guelﬁ et al.58 including overweight and obese men
found that neither endurance nor resistance training signiﬁcantly
altered fasting and postprandial levels of PYY despite aerobic
training being associated with increased satiety.58 Thus, evidence
on the contribution of PYY to improved satiety during weight loss
with exercise training remains controversial. The impact of a single
exercise session on PYY response is more obvious, with most
acute studies reporting a small increase in PYY levels immediately
after exercise.45 This increase is consistent with the notion that
acute increases in PYY can be expected to induce suppression of
hunger and potentially diminish compensation for the expended
energy. To date, no studies have been published investigating the
impact of acute exercise on peptide YY responses in overweight
and obese individuals.
Pancreatic polypeptide. Pancreatic polypeptide (PP) is produced
under vagal control by the peripheral cells of the endocrine
pancreatic islets, and to a lesser extent in the exocrine pancreas,
colon, and rectum in response to a meal and to insulin-induced
hypoglycemia (Table 1).16,59,60 In humans, administration of
pharmacological doses of PP has been shown to decrease food
intake.22 Furthermore, PP inhibits the gastric emptying rate,
exocrine pancreatic secretion and gallbladder motility.60 Studies of
PP in obese humans have demonstrated conﬂicting results. Some
studies found no difference between lean and obese subjects,61
whereas other studies demonstrated lower fasting PP levels in
obese subjects.62 If PP levels are decreased in obese subjects, then
this could reﬂect a consequence of being overweight or, on the
other hand, be a cause of being overweight as PP affects food
intake.
Evidence of the effect of weight loss on PP concentrations in
obese individuals is inconsistent.42,43,62,63 In one study, both
postprandial PP concentrations and subjective ratings of hunger
were increased after diet-induced weight loss and stabilization;
the alterations persisted for at least 1 year after the initial weight
loss.43 An increase in PP concentration following weight loss was
also found in obese children.62 Thus, it could be assumed that the
direction of change in PP following diet-induced weight loss is
different from that reported in other gut hormones. However,
fasting levels of PP, as with other anorexigenic gut hormones
measured, were found to be reduced and appetite scores were
increased in obese patients who experienced weight loss (in
response to a short-term, low-energy diet) and weight stabilization
compared with the same patients after they experienced some
Figure 2. PYY responses 90min after each of six test meals of
increasing caloric content in 20 obese and 20 normal-weight
subjects. *Po0.05 (unpaired t-test).49 Reproduced with permission.
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weight regain. In addition, postprandial levels of the gut hormone
increased compared with fasting, but signiﬁcant differences
between before and after weight regain were not apparent.42,43
Literature regarding the impact of exercise on PP is scarce and
limited to acute exercise studies. As with GLP-1 and PYY, the
recent meta-analysis found that a single exercise session increases
the area under the PP concentration versus time curve.45 This
exercise session-induced increase in PP can potentially contribute
to appetite reduction reported during the hours immediately after
exercise.
Cholecystokinin. Cholecystokinin (CCK) is produced in duodenal
and jejunal ‘I’ cells and secreted in response to luminal nutrient
(particularly fat) intake (Table 1).22,64,65 Structurally, CKK is related
to gastrin and it exists in numerous molecular forms with different
numbers of amino acids, for example, CKK-8, CKK-33 and
CKK-39.66,67 The main effect of CCK on the GI system is to
facilitate nutrient absorption, stimulate gall bladder contraction,
enhance pancreatic enzyme secretion and slow gastric
emptying.68–70 Delayed gastric emptying has been considered as
a central mechanism by which CCK suppresses appetite.71 CCK is
also present in different parts of the brain such as the amygdala,
cortex, hippocampus, thalamus, hypothalamus, septum, dorsal
hindbrain and basal ganglia, acting as a neurotransmitter.67,69,72
Compared with baseline measures, mean postprandial plasma
concentrations of CCK were reduced in overweight and obese
subjects who had lost a mean of 14% of their of initial weight after
an 8-week very low-energy diet and a 2-week weight stabilization
phase.43 Reductions in CCK levels persisted during the 1-year
weight maintenance period. Similarly, rapid weight loss of
approximately 15% of body weight in obese men who partici-
pated in a very-low-calorie diet intervention for 8 weeks and
1 week of weight stabilization resulted in signiﬁcantly decreased
postprandial CCK concentrations compared with baseline.73 These
two studies suggest that CCK is reduced following rapid weight
loss, a mechanism that might favour increased appetite and
weight regain, and thus have a survival value. Both studies
included a weight stabilization phase of 1–2 weeks; however, it is
not certain whether this is sufﬁcient for full metabolic adaptation
to a neutral energy balance in overweight and obese subjects.
Evidence regarding the effect of exercise on CCK concentration,
as with PP, is very limited. The recent study by Martins et al.74
reported that a 12-week exercise programme undertaken by
overweight and obese sedentary individuals induced an average
3.5 kg weight loss but had no signiﬁcant effect on either fasting or
postprandial concentrations of CCK measured at least 48 h after
the last exercise session to exclude the acute effects of exercise.
The same study also found that exercise improved the ability to
differentiate between preloads with different energy content. This
implies that modiﬁcations in eating behaviour commonly seen
with exercise are probably related to changes in levels and/or
sensitivity of other appetite-regulating hormones and, as
discussed in Supplementary information, alterations in neuronal
responses to food. So far, data on the impact of acute exercise on
CCK levels are available only from studies conducted on normal-
weight individuals. These studies have reported increased CCK
responses immediately after exercise and for up to 2 h.75,76 This
signiﬁcant increase in CCK concentrations observed in acute
exercise studies is in line with suppressed hunger feelings
reported during the immediate hours after exercise.77
Leptin. Leptin is a key adiposity hormone produced tonically by
mainly white adipose tissue. Secretion increases as lipid content
rises and it signals to receptors in the hypothalamus to reduce
appetite and increase energy expenditure (Table 1).78 The main
physiological role of leptin is probably through its suppression,
during starvation and thinness, to increase appetite; when normal
body fat content is restored, leptin is again secreted. Leptin also
has a role in promoting fertility.79 Recent evidence suggests that
leptin potentiates the effects of CCK on inhibition of food intake
and that this interaction is disrupted in obesity.80 Humans with
rare mutations in the leptin or leptin receptor gene suffer extreme
early-onset obesity and have endocrine defects.81,82 Obesity and
other consequences of leptin deﬁciency are corrected by long-
term replacement therapy, so it appears certain that leptin has a
key function in the regulation of energy balance in humans.
However, in studies of adult humans, leptin concentrations
correlated with total fat mass and appear to have little inﬂuence
on energy intake. Leptin levels are decreased in patients with
anorexia nervosa in a state of semi-starvation; during refeeding,
levels increase in a BMI-dependent manner.83
In one study of lean and severely obese women, leptin levels
were measured after a 12-h fast (baseline), and then over a 2-h
period (measured at 0, 15, 30, 60, 90 and 120 min) following
ingestion of a body weight-adjusted test meal (approximately
one-quarter of the woman’s kcal needs; range, 576.1–803.8 kcal;
60% carbohydrate, 20% protein and 20% fat).84 Baseline leptin
levels were signiﬁcantly higher in the obese subjects at baseline.
These levels decreased gradually over the ﬁrst 90 min after the
test meal and precipitously thereafter (at 120min). This is in
contrast to lean subjects in whom leptin levels remained relatively
constant over the 2-h postprandial period. In another study,
baseline leptin levels were also higher in obese subjects compared
with lean controls; levels did not change in either group during
the ﬁrst 60 min following a test meal of up to 510 kcal.39 Higher
circulating concentrations of baseline leptin in obese individuals,
with greater fat masses, are not surprising. However, because
leptin promotes satiety, these studies support the notion that
obese individuals exhibit some type of central leptin resistance
that disrupts the satiety response. In two studies, diet-induced
weight loss of approximately 15% of initial body weight in obese
subjects resulted in fasting leptin levels that were 35% lower than
baseline and remained reduced compared with baseline for up to
1 year after weight loss and stabilization.43,85 The role of leptin in
satiety was further examined in obese subjects who underwent a
weight reduction programme and stabilization at 10% below their
initial weight.86 Subjects received subcutaneous ‘replacement
doses’ of recombinant human leptin or placebo twice daily for
5 weeks each. After ingesting a liquid-formula diet, subjects
reported signiﬁcantly higher levels of satiation on a visual
analogue scale following leptin than following placebo injections.
These studies further support the role of leptin in the regulation of
satiety and suggest that leptin resistance might to some extent be
overcome by massive weight loss. A role for physical activity,
permitting transport of leptin into the brain, has also been
proposed as a way to overcome leptin resistance.87
The notion that participation in exercise improves the activity of
leptin is supported by evidence that exercise, when associated
with mass loss, is followed by a signiﬁcant reduction in fasting
leptin concentrations and that this change increases rather than
reduces subjective hunger measured in the fasted state.88
A recent study reported that exercise-induced weight loss leads
not only to a reduction in fasting, but also in postprandial,
concentrations of leptin.74 Another study involving a 12-week
supervised exercise programme in sedentary overweight and
obese individuals suggested that leptin concentrations measured
both in the fasted state and after high- and low-energy test meals
were signiﬁcantly lower following exercise intervention, resulting
in up to approximately 3.5 kg of weight loss.74 Despite this, the
accuracy of compensation for previous energy intake was
improved. Thus, reduced leptin concentrations after chronic
exercise might indeed reﬂect improved leptin action.
Ghrelin. Ghrelin is a 28-amino acid peptide originally identiﬁed
as the endogenous ligand of the growth hormone secretagogue
receptor 1a (GHS-R1a);89 besides having growth hormone-
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releasing activity, it is a potent orexigen with a fundamental
inﬂuence on appetite and energy homeostasis regulation.7,18
Ghrelin is primarily expressed in the stomach as well as in the
hypothalamus. The orexigenic functions of ghrelin have been
attributed to total and acylated ghrelin, while unacylated form
(490% of total ghrelin) has been considered as a non-functional
peptide.90 Ghrelin concentration peaks in response to fasting and
anticipation of the coming meal,91 and thus initiates and
promotes eating (Table 1). Concentrations in normal-weight
individuals exhibit a preprandial peak with a decline after
eating.92 Working in opposition to satiety hormones, ghrelin
increases the rate of gastric emptying93 and increases hunger.94
However, some recent data do not favour a role of peripheral
ghrelin in the regulation of food intake.95,96 First, ghrelin infusion
at both physiological and supraphysiological doses was found to
have no effect on appetite or spontaneous meal request.95 In
addition, it has been reported that food restriction-induced
increases in appetite were not inﬂuenced by changes in plasma
acylated ghrelin concentrations. At the same time over the past
few years, effects of unacylated ghrelin on insulin sensitivity,
metabolism, muscle regeneration and β-cell protection have been
reported.97,98 Regardless of the current debate about the primary
function of ghrelin, research investigating the role of this hormone
in appetite regulation deserves discussion.
Fasting and postprandial plasma ghrelin levels were reported to
be lower in obese than in normal-weight individuals (Figure 3).84
Little change from fasting levels was noted in obese subjects in
other studies.39,50,55,84,85,99 One of these studies demonstrated a
30% reduction from preprandial ghrelin levels in lean women,
beginning 30min after a test meal, but no signiﬁcant changes
were noted in either obese or severely obese women.55 There may
be nutrient-speciﬁc effects on ghrelin levels. Yang et al.50 found
greater postprandial suppression of ghrelin in obese and lean
subjects following a high-carbohydrate meal (88% carbohydrate,
8% protein and 4% fat) than after a high-fat meal (25%
carbohydrate, 4% protein and 71% fat). However, compared with
lean subjects, obese subjects demonstrated less suppression of
ghrelin following either meal.
Thus, observations of the relationship between obesity and
failure to suppress ghrelin levels after a meal are consistent across
studies. The ﬂattened hormone proﬁles around traditional
mealtimes may be a factor in the continuous ‘grazing’ pattern
reported in obese subjects.100,101
Diet-induced weight loss in obese subjects was accompanied
by alterations in ghrelin levels in several studies. Compared with
baseline measures, plasma ghrelin was increased by 17% in
overweight and obese women who reduced their body weight by
4.5% at the completion of a 10-week weight loss intervention
programme that included an energy-restricted diet of 40%
carbohydrates, 30% fat and 30% protein.102 It should be noted
that these results were obtained at the end of the acute
intervention, and thus participants were presumably still in a
state of negative energy balance, which may have confounded
the results. In two other studies, short-term diet-induced weight
loss in obese subjects resulted in an exaggerated pattern of
postprandial changes in ghrelin levels compared with the pre-
weight loss setting, with signiﬁcantly greater levels persisting over
weight maintenance/stabilization periods of 6 and 12 months.43,85
Repeated weight loss and regain may result in long-term
alterations in ghrelin signalling. Among 159 weight-stable obese
or overweight women, a history of intentional weight loss over the
preceding 20 years, deﬁned as episodes of intentionally losing at
least 10 pounds, and frequency of intentional weight cycling were
associated with higher fasting levels of ghrelin, in analyses
adjusted for age, BMI and physical activity.103 This evidence raises
the intriguing possibility that, as well as weight loss, weight
cycling may promote an appetite-stimulating hormonal proﬁle,
further hindering weight maintenance. However, reaching this
conclusion hinges on effective adjustment of the data for
confounders, of which the most important is body composition;
relatively small differences in body composition may introduce
errors, and BMI is not sufﬁciently speciﬁc to avoid these errors.
The role of ghrelin in the control of appetite has been examined
extensively in exercise studies. A recent meta-analysis reported
that in normal-weight individuals, acute exercise suppresses
acylated ghrelin levels,45 in line with a transient suppression of
hunger in the hours immediately after exercise.104 However,
chronic exercise resulting in signiﬁcant weight loss was found to
enhance fasting concentrations of total105 and acylated44 ghrelin
in obese and overweight individuals. At the same time, increased
suppression of postprandial acylated ghrelin was observed in one
of the studies.44 This is in line with the observation that although
medium-term exercise-induced weight loss increases both fasting
hunger and hunger across the day, it also improves meal-induced
satiety.106
In contrast to the above results, a study conducted in a group of
morbidly obese men and women showed that fasting and meal
related circulating ghrelin levels remained unchanged despite 5%
weight loss induced by a 3-week integrated body weight
reduction programme with exercise training.107 No impact of
aerobic training on circulating acylated ghrelin levels was found in
a study conducted on overweight and obese men58 and
overweight children.108 Differences in fat mass loss, volume and
duration of exercise interventions, and inclusion of different
genders are likely to be factors contributing to the discrepancy. In
addition, changes in ghrelin concentration with exercise may be
also dependent on extent and direction of change in levels of
other potential appetite regulators, such as a leptin, insulin and
probably PYY.109,110
Effect of corticosteroids on gut peptides
Elevated corticosteroid status provides a useful model for some
types of obesity. Weight gain varies widely in human clinical
studies, depending on dose/circulating concentration and on
individual factors. Alterations in the hypothalamic–pituitary–
adrenal axis have been demonstrated in obesity.111 Weight gain
is a feature of Cushings syndrome and a common side effect of
Figure 3. Ghrelin responses to a test meal in 10 normal-weight and
13 severely obese women. Ghrelin levels were signiﬁcantly higher.
*(P⩽ 0.05) in normal-weight women at baseline (P= 0.001) and at 15
(P= 0.001), 60 (P= 0.032) and 120 (P= 0.044) min postprandially.84
Reproduced with permission.
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glucocorticoid therapy. A systematic review has suggested an
average weight gain of 2 kg, but the stringent inclusion criteria of
that review resulted in only one RCT paper being included.112 It is
surprising that weight change with corticosteroids, which can
often be large, has not been better documented. Therapeutic
doses of glucocorticoids were shown to increase food intake in
healthy male volunteers (N= 10).113 Vicennati et al.114 reported
weight gain and the development of obesity in women (N= 14)
after a signiﬁcant stressful event; these changes were manifested
via a hyperactive adrenal cortex.114 In another study, stress-related
cortical secretion was positively correlated with BMI, waist-to-hip
ratio and sagittal recumbent trunk diameter in a population of
51-year-old men (N= 284).115 In a study examining the effects of
methodology on gut hormone levels in 10 normal-weight men,
the temporal plasma PYY concentration proﬁle was altered by
study-induced stress, and the PYY area under the curve was
positively correlated with the cortisol area under the curve.116 In
33 young adults, serum ghrelin exhibited a strong inverse
association with serum cortisol during 12–84 h of fasting
(r=− 0.79; Po0.0001).117 However, in a separate study, predni-
sone treatment (30 mg day− 1 for 5 days) signiﬁcantly suppressed
plasma ghrelin levels by a median of 18.3% in eight healthy
volunteers; thus, the authors concluded that weight gain observed
with glucocorticoid treatment may not be mediated by ghrelin.118
CONCLUSIONS
Obesity in humans arises from excess energy consumption relative
to expenditure over long periods, with secondary hyperphagia
that opposes weight loss. Although adult eating patterns are
inﬂuenced substantially by social, cultural and commercial factors,
food intake is also regulated by a complex and inter-connected
array of peripheral hormonal signals, originating in the gut and
adipose tissue in humans.
The list of peripheral hormones that regulate appetite and food
intake is long and growing. Studies related to gut and adipose
tissue hormones and obesity suggest that obesity is associated
with a blunted postprandial response of satiety factors such as
GLP-1 and PYY, CCK and reduced postprandial suppression of
orexigenic ghrelin, and some type of central leptin resistance.
Caloric restriction-induced weight loss causes persistent changes
in peripheral hormones that tend to increase appetite and
promote weight regain, while bariatric surgery and exercise
programmes modify responses in a direction expected to enhance
satiety and permit weight loss and/or maintenance. This
suggestive causal relationship between weight loss following
caloric restriction, exercise and gastric bypass surgery (see
Supplementary information) and peripheral hormone alterations
was not found in all studies.
Research into the regulation of appetite and body weight has
seen a dramatic increase in the last 20–30 years, as the obesity
epidemic has emerged, and the recognition of adipose tissue as
an active endocrine organ is one of the most remarkable
paradigm shifts of the last 100 years. Future research must focus
clearly between causal factors in the disease process of obesity and
physiological changes and adaptations to the state of obesity.
Simply measuring differences between obese and non-obese
individuals can be misleading. To unravel and begin to correct the
causes of the obesity epidemic there is a need for more studies on
longitudinal changes, and on the interactions between potential
factors in this complex, multifactorial disease. The principle drivers
of the epidemic seem clearly to be social, with both reduced
physical activity and greater provision and promotion of energy-
dense foods contributing. It is now incontrovertible that endocrine
factors are playing a part, but the extent to which their roles are
causal needs deﬁnition. The extent to which interventions via
endocrine systems can ameliorate the situation for obese people
will be deﬁned by ongoing and planned clinical research, but
modern analogue therapies appear to offer remarkably low-risk
and effective treatments when used in conjunction with
nutritionally-sound evidence-based diet and exercise regimens.
Taken together, the research ﬁndings presented in this review
are building a foundation for the identiﬁcation of targets for life
style and therapeutic interventions in obesity. Ongoing research
will further our understanding of the effects of obesity on body
weight homeostasis and potentially enable us to exploit, at least
for some obese individuals, the effects of gut and adipose tissue
hormones involved in the regulation of appetite.
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